Related Experiment Videos
Hemodynamic effects of metoprolol in acute myocardial infarction. A randomized, placebo-controlled multicenter study
Insights
Metoprolol effectively reduced heart rate and blood pressure in acute myocardial infarction patients. The drug demonstrated good hemodynamic tolerance, even in those with initially high pulmonary capillary wedge pressure.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Acute myocardial infarction (AMI) management requires careful consideration of hemodynamic stability.
- Beta-blockers, like metoprolol, are crucial in AMI treatment but require cautious administration.
- Understanding metoprolol's central hemodynamic effects is vital for optimizing AMI patient care.
Purpose of the Study:
- To evaluate the central hemodynamic effects of intravenous and oral metoprolol in patients with acute myocardial infarction.
- To assess the safety and tolerance of metoprolol administration in this patient population.
- To compare hemodynamic changes induced by metoprolol versus placebo.
Main Methods:
- A multicenter, double-blind, randomized trial involving 190 AMI patients.
- Patients received either metoprolol (intravenous and oral) or placebo, with pulmonary artery catheterization for hemodynamic monitoring.
- Measurements included heart rate, blood pressure, cardiac index, and pulmonary capillary wedge pressure over 24 hours.
Main Results:
- Metoprolol significantly reduced heart rate, systolic blood pressure, and cardiac index by 10-20% compared to placebo.
- Pulmonary capillary wedge pressure transiently increased in some patients but was well-tolerated.
- No intolerance was observed in patients with initially high pulmonary capillary wedge pressure.
Conclusions:
- Metoprolol exerts significant central hemodynamic effects in acute myocardial infarction patients.
- The drug is well-tolerated hemodynamically, supporting its use in selected AMI patients.
- Early metoprolol administration can be safely managed based on hemodynamic parameters.
Abstract:
The central hemodynamic effects of metoprolol in acute myocardial infarction have been studied in a multicenter, double-blind, randomized trial. One hundred and ninety patients with acute myocardial infarction not previously on beta blockers with heart rate greater than 65 beats/min and blood pressure greater than 105 mm Hg and without clinical signs of serious heart failure were included. After insertion of a pulmonary artery catheter, patients were randomized to metoprolol, 15 mg intravenously, and 50 mg 4 times a day orally (n = 95) or placebo (n = 95) with a mean delay of 7.2 hours. Hemodynamic measurements were made at baseline and repeatedly during 24 hours. Heart rate, systolic blood pressure and cardiac index were all immediately reduced by 10 to 20% in the metoprolol group and the difference compared with placebo was maintained throughout the 24 hours (p less than 0.001). Pulmonary capillary wedge pressure (PCWP) in the metoprolol group increased from 13.7 +/- 6.7 to a peak of 15.5 +/- 5.5 mm Hg 30 minutes after injection. The difference compared with placebo was maintained for 8 hours (p less than 0.01). This increase was seen only in the patient group with initial PCWP below the median of 13 mm Hg. In patients with initial PCWP above the median a continuous decrease was observed in both the placebo and metoprolol groups. Thus high initial PCWP was not associated with intolerance to metoprolol. Based on hemodynamic measurements tolerance to metoprolol was good.